LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Начало・Списък с акции・Pulmatrix Inc

Pulmatrix Inc

Затворен

2.19 -5.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.14

Максимум

2.32

Ключови измерители
By Trading Economics
Приходи	-51K -928K
EPS	-0.24
Марж на печалбата	-60,266.667
Служители	2
EBITDA	-51K -928K

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.6M 7.8M
Предишно отваряне	7.79
Предишно затваряне	2.19

Pulmatrix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.03.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23.03.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23.03.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

23.03.2026 г., 23:59 ч. UTC

Пазарно говорене

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

23.03.2026 г., 22:42 ч. UTC

Пазарно говорене

Значими събития в новините

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23.03.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23.03.2026 г., 22:23 ч. UTC

Пазарно говорене

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23.03.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23.03.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23.03.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23.03.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23.03.2026 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23.03.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23.03.2026 г., 22:08 ч. UTC

Пазарно говорене

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.03.2026 г., 21:42 ч. UTC

Пазарно говорене

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23.03.2026 г., 21:32 ч. UTC

Печалби

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23.03.2026 г., 21:10 ч. UTC

Значими събития в новините

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

23.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Значими събития в новините

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pulmatrix Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Pulmatrix Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.